Bruker Introduces maXis HD Ultra-High Resolution QTOF
At the 12th Human Proteome Organization World Congress (www.hupo.org/2013), Bruker completed its series of High-Definition (HD) QTOF systems introductions with the launch of its new flagship maXis HD ultra-high resolution (UHR) QTOF mass spectrometer. With its best-in-class full sensitivity resolution (FSR) greater than 75,000, the new maXis HD is ideally suited for top-down proteomic analyses and the characterisation of biopharmaceuticals.
The novel maXis HD features a new High-Definition Collision (HDC) cell which enables its record-breaking full sensitivity mass resolution, as well as accurate mass capabilities well beyond all competing QTOF As a result of its extreme sensitivity broad mass-transfer ion optics and the fastest available 50 Gbit/s sampling technology, a dynamic range of five orders of magnitude is achieved in one second of LC time. High dynamic range at high speed is a prerequisite for high-resolution detection of low-abundance compounds in sharp UHPLC peaks and permits direct identification and quantitation without re-runs.
The maXis HD offers break-through analytical performance for applications in top-down proteomics and in biopharmaceutical compound analysis, and the instrument excels in the analysis of intact proteins and antibodies. For antibody subunits, it can provide unprecedented insight into antibody structures via its ultra-high resolution at high mass with baseline discrimination of isotope envelopes at excellent mass accuracy.
The maXis HD also delivers a new confidence level in the fast, high-resolution, accurate mass screening, identification and quantification of small molecules. The novel HDC cell and HD detection technology translate directly into enhanced dynamic range and extreme sensitivity down to very low masses at UHPLC speed, a precondition for one-shot plug and play acquisitions in multi-target applications. The recording-breaking full sensitivity resolution in combination with the Bruker proprietary, real-time SmartFormula 3D software makes the maXis HD the tool of choice for true unknown screening and the ab initio determination of elemental composition at UHPLC speed and throughput.
Dr Michael Schubert, President of the Bruker Daltonics Life-Science & Clinical Division, stated: “With these performance features we believe that the new maXis HD delivers the fastest time-to-success for customers across a broad applications portfolio, covering small molecule identification and characterisation; food, forensic and environmental screening; metabolomics; as well as top-down proteomics and antibody analysis."
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...